1. Fc-binding nanodisc restores antiviral efficacy of antibodies with reduced neutralizing effects against evolving SARS-CoV-2 variants.
- Author
-
Hwang, Jaehyeon, Choi, Soyun, Kim, Beom Kyu, Son, Sumin, Yoon, Jeong Hyeon, Kim, Kyung Won, Park, Wonbeom, Choo, Hyunjoo, Kim, Suhyun, Kim, Soomin, Yu, Seokhyeon, Jung, Sangwon, Jung, Sang Taek, Song, Min-Suk, Kim, Sang Jick, and Kweon, Dae-Hyuk
- Subjects
SARS-CoV-2 Omicron variant ,COVID-19 pandemic ,INTRANASAL administration ,CHIMERIC proteins ,SARS-CoV-2 ,IMMUNOGLOBULINS - Abstract
Passive antibody therapies, typically administered via parenteral routes, have played a crucial role in the initial response to the COVID-19 pandemic. However, the ongoing evolution of SARS-CoV-2 has revealed significant limitations of this approach, primarily due to mutational escape and the inadequate delivery of antibodies to the upper respiratory tract. To overcome these challenges, we propose a novel prophylactic strategy involving the intranasal delivery of an antibody in combination with an Fc-binding nanodisc. This nanodisc, engineered to specifically bind to the Fc regions of IgG antibodies, served two key functions: extending the antibody's half-life in the larynx and trachea, and enhancing its neutralization efficacy. Notably, Sotrovimab, an FDA-approved monoclonal antibody that has experienced a significant decline in neutralizing potency due to viral evolution, exhibited robust antiviral activity when complexed with the nanodisc against all tested Omicron variants. Furthermore, the Fc-binding nanodisc significantly boosted the antiviral efficacy of the soluble angiotensin-converting enzyme 2 (sACE2) Fc fusion protein, which possesses broad but modest antiviral activity. In ACE2 transgenic mice, the Fc-binding nanodisc protected better than sACE2-Fc alone with two more log reduction in lung viral titer. Therefore, the intranasal Fc-binding nanodisc offers a promising and powerful approach to counteract the diminished antiviral activity of neutralizing antibodies caused by mutational escape, effectively restoring antiviral efficacy against various evolving SARS-CoV-2 variants. [ABSTRACT FROM AUTHOR]
- Published
- 2025
- Full Text
- View/download PDF